Trial Profile
A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Lorvotuzumab mertansine (Primary)
- Indications Nerve sheath neoplasms; Neuroblastoma; Pulmonary blastoma; Rhabdomyosarcoma; Synovial sarcoma; Wilms' tumour
- Focus Adverse reactions; Therapeutic Use
- 04 Jan 2022 Status changed from active, no longer recruiting to completed.
- 28 Aug 2019 Planned End Date changed from 1 Mar 2020 to 31 Dec 2021.
- 06 Jun 2017 Results assessing the efficacy and tolerability of lorvotuzumab mertansine at the adult recommended phase 2 dose in children with relapsed tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.